期刊文献+

血管内皮生长因子及受体Flt-1在膀胱癌中的表达及意义 被引量:6

Expression of VEGF and the receptor in bladder carcinoma and clinical significance
下载PDF
导出
摘要 目的探讨血管内皮生长因子 (VEGF)及其受体Flt 1在膀胱癌血管生成中的作用及与膀胱癌分化程度的关系。方法采用免疫组化S P法对 4 0例膀胱癌及 5例正常膀胱组织中VEGF、Flt 1蛋白进行检测。结果VEGF及其受体Flt 1主要分布在膀胱癌组织血管内皮细胞和癌细胞胞质内 ,VEGF及Flt 1在G3(低分化 )膀胱癌血管内皮细胞和癌细胞中的表达高于G2 (中分化 )和G1(高分化 )并且明显高于正常组织 (P <0 0 1)。结论VEGF和其受体Flt 1与膀胱肿瘤的分级和分期密切相关 ,可以作为判断膀胱癌生长和浸润的指标之一。 Objective The relationship between the expression of vascular endothelial cell growth factor (VEGF), the receptor Flt-1, the pathological types and clinical stages in bladder cancers were studied. Methods The expression of the receptor Flt-1 and VEGF in the 40 cases bladder cancer and 5 cases normal bladder tissues were assayed by immunohistochemical of S -P with the VEGF and the Flt-1 polyclonal antibody. Results The VEGF and receptor Flt-1 were widely expressed in the cytoplasm of endothelial cells and tumor cells of endometrial carcinoma. The level of VEGF and Flt-1 proteins in the endothelial cells and bladder cancer cells of grade II and III tumor tissues were higher than that in grade I and normal bladder tissues (P<0.01).Conclusion Expression of VEGF and Flt-1 related to the pathological types and clinical stages of bladder cancers. They could be used as the useful indexes reflecting the biological behavior and might be considered to be a reference indicator for judging prognosis and selecting clinical therapy of bladder carcinoma.
出处 《贵州医药》 CAS 2004年第9期779-782,共4页 Guizhou Medical Journal
关键词 血管内皮生长因子 受体FLT-1 膀胱癌 基因表达 VEGF 肿瘤 免疫组化 VEGF Flt-1 Bladder carcinoma Immunohistochemistry
  • 相关文献

参考文献8

  • 1Jeremy PC, Tim O, Mike B, et al. Vascular endothelial growth factor is a predictor of replase and stage progression in superficial bladder cancer[J]. Cancer Res, 1997,57(5):5 281-5 285.
  • 2Thaloor D, Singh AK, Sidhu GS, et al. Inhibition of angiogenic differentiation of humen umbilical vein endothelial cells by cureumin. Cell Growth Differ, 1998,9 (4): 305 -312.
  • 3Cao Y. Therapeutic potentials of angiostatin in the treatment of cancer. Haematologica, 1999,84(7): 643-650.
  • 4O' Brien T, Cranston D, Fuggle S, et al. Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res, 1995,55(3) :510-513.
  • 5Crew JP, O' Brien T, Bicknell R, et al. Urinary vascular endothelia growth factor and its correlation with bladder cancer recurrence rates. J Urol, 1999,161 (3) : 799 -804.
  • 6Crew N H,Lir HS,Chan SH, et al. Expression of vascular endothelial growth factor in primary superficial bladder cancer. Anticancer Res, 1999,19(5c) :4 593-4 597.
  • 7Jones A, Crew J. Vascular endothelial growth factor and its correlation with superficial bladder cancer rates and stage progression. Urol Clin North Am, 2000,27(1): 188 -191.
  • 8罗旭,李道兵,赵泽驹,梁国标,李栋.表皮生长因子在膀胱癌中的表达及意义[J].贵州医药,2003,27(4):294-295. 被引量:4

二级参考文献3

  • 1[1]Downward J,Yarder Y,Mayas E.Close similarity of epidermal growth factor receptor and C-erbB oncogene sequence.Nature,1984,307:529~531.
  • 2[2]Tanaka S.Immunoreactive transforming growth factor in colorectal adenomas and carcinomas.Oncology,1992,49(5):381~385.
  • 3[3]Tahara E.Human epidermal growth factor in gastric carcinoma as a biologic marker of high malignancy.Jpn J Cancer Res,1986,77(2):145~147.

共引文献3

同被引文献26

引证文献6

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部